You searched for "age"
RaScaL Study
The RaScaL study was a six month, single-centre, controlled, prospective phase I/II study in which subjects with diabetic macular oedema (DME) and associated peripheral nonperfusion on ultrawide-field fluorescein angiography (UWFA) were randomised to: (1) study arm: ranibizumab (0.5 mg) injection...
Efficacy of intravitreal dexamethasone implant in patients with persistent macular oedema
Chronic cystoid macular oedema (CME) can develop secondary to various pathologies such as diabetic maculopathy, retinal vein occlusion and uveitis. It can cause significant visual impairment and macular damage. The therapeutic effect of corticosteroids in CME is through one or...
Four key questions and answers for glaucoma practitioners
In this discussion paper the authors pose four questions for the clinician diagnosing and monitoring glaucoma, and supply evidence-based answers. Worldwide, the most common functional test used to diagnose and monitor glaucoma is static automated perimetry, most typically with a...
Incidence and risk factors of ocular hypertension following PPV and SOI
In this prospective, interventional study the authors evaluated the risk factors for elevated intraocular pressure (IOP) after pars plana vitrectomy (PPV) with silicone oil injection (SOI). This study included 254 eyes of 254 patients, with a mean age of 55.33...
Suture-less flanged IOL fixation vs. conventional sutured SF in IOL dislocation
The authors report the analysis of a prospective, comparative cohort study on 103 consecutive patients (103 eyes) with intraocular lens (IOL) dislocation who underwent vitrectomy with IOL removal and sutured scleral fixation (SF) (53 eyes) or flanged IOL fixation (50...
Detecting apoptosis in retinal cells
This is a review paper in which the authors summarise the transitioning of techniques detecting apoptosis from bench to bedside, along with the future possibilities they encase. Detection of Apoptosis in Retinal Cells (DARC) technology can be used as a...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...
